Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Renal Cell Carcinoma

Research provides new kidney cancer clues

Researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer. The identification of a frequently mutated gene will provide new insights into the biology of the disease. This biological knowledge will be critical in the continued effort to improve treatment for renal cancer.… Research provides new kidney cancer clues   



Kidney cancer discovery could expand treatment options

Oregon Health & Science University Knight Cancer Institute researchers uncovered a gene that may be the key to helping kidney cancer patients who don’t respond to current therapies. This discovery could also provide a toolkit to identify patients who are most likely to benefit from drugs that block this gene from causing cancer cells… Kidney cancer discovery could expand treatment options   



Lymphocyte count indicates the prognosis of patients with renal cell carcinoma

Each year, kidney cancer is diagnosed in nearly 60,000 people in the U.S. Many of these patients undergo surgery to remove the affected kidney, but this procedure can be risky for the elderly and those who have other health problems. Unfortunately, the prognosis of kidney cancer patients often cannot be determined until tumor samples… Lymphocyte count indicates the prognosis of patients with renal cell carcinoma   



Arsenic linked to kidney cancer

People with moderately elevated levels of arsenic in their urine may have an increased risk of kidney cancer—particularly if they have high blood pressure and kidney disease, a new study suggests.

The findings, reported in the Journal of Urology, do not prove that arsenic contributes to kidney cancer, however. One possibility, the researchers say,… Arsenic linked to kidney cancer   



Dartmouth researchers test safety of Nivolumab in kidney cancer

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma (mRCC) at the ASCO Annual Meeting on June 3, 2013.

Metastatic renal cell carcinoma or kidney… Dartmouth researchers test safety of Nivolumab in kidney cancer   



peritoneum1 - bacteriuria2 - salt1 - chronic kidney disease in children1 - microscopic hematuria1 - kidney function18 - urinary stasis1 - tras1 - zygote intrafallopian transfer1 - polyarteritis1 - external sphincter dyssynergia1 - bloody diarrhea1 - mortality risk1 - atherosclerosis1 - recurrence of cancer1 - active surveillance1 - stone recurrence1 - overactive bladder9 - kidney infection4 - birth control2 - infections1 - heart surgery2 - teen pregnancy1 - focal glomerulosclerosis2 - sphincter deficiency4 - prognostic tests1 - focused ultrasound surgery foundation1 - urine production1 - ct3 prostate cancer1 - intermittent therapy1 -